Published in Am J Trop Med Hyg on June 25, 2001
A pilot randomised trial of induced blood-stage Plasmodium falciparum infections in healthy volunteers for testing efficacy of new antimalarial drugs. PLoS One (2011) 1.47
Antiparasitic agent atovaquone. Antimicrob Agents Chemother (2002) 1.41
Therapy of uncomplicated falciparum malaria in Europe: MALTHER - a prospective observational multicentre study. Malar J (2012) 1.10
Atovaquone-proguanil in the treatment of imported uncomplicated Plasmodium falciparum malaria: a prospective observational study of 553 cases. Malar J (2013) 0.81
Malaria Prevention Strategies: Adherence Among Boston Area Travelers Visiting Malaria-Endemic Countries. Am J Trop Med Hyg (2015) 0.79
Artemether-lumefantrine compared to atovaquone-proguanil as a treatment for uncomplicated Plasmodium falciparum malaria in travelers. Am J Trop Med Hyg (2014) 0.75
Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique. Antimicrob Agents Chemother (1979) 17.49
Averting a malaria disaster. Lancet (1999) 9.40
Identification of a platelet membrane glycoprotein as a falciparum malaria sequestration receptor. Science (1989) 3.83
Atovaquone-proguanil versus mefloquine for malaria prophylaxis in nonimmune travelers: results from a randomized, double-blind study. Clin Infect Dis (2001) 3.43
Primary structure of the 175K Plasmodium falciparum erythrocyte binding antigen and identification of a peptide which elicits antibodies that inhibit malaria merozoite invasion. J Cell Biol (1990) 3.11
What is wrong with end-of-life care? Opinions of bereaved family members. J Am Geriatr Soc (1997) 2.96
Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in non-immune travellers: a randomised, double-blind study. Malarone International Study Team. Lancet (2000) 2.92
Molecular basis of sequestration in severe and uncomplicated Plasmodium falciparum malaria: differential adhesion of infected erythrocytes to CD36 and ICAM-1. J Infect Dis (1991) 2.87
What is known about the prevention of congenital toxoplasmosis? Lancet (1990) 2.78
Can clinical interventions change care at the end of life? Ann Intern Med (1997) 2.71
Differences in end-of-life decision making among black and white ambulatory cancer patients. J Gen Intern Med (1996) 2.67
Quantitation of amastigotes of Leishmania donovani in smears of splenic aspirates from patients with visceral leishmaniasis. Am J Trop Med Hyg (1983) 2.57
Clinical manifestations of Plasmodium falciparum malaria experimentally induced by mosquito challenge. J Infect Dis (1997) 2.55
Guidance for contained field trials of vector mosquitoes engineered to contain a gene drive system: recommendations of a scientific working group. Vector Borne Zoonotic Dis (2008) 2.49
Imported Falciparum malaria in Europe: sentinel surveillance data from the European network on surveillance of imported infectious diseases. Clin Infect Dis (2002) 2.44
Primary structure of a Plasmodium falciparum malaria antigen located at the merozoite surface and within the parasitophorous vacuole. J Biol Chem (1988) 2.43
In vitro evaluation of the pneumocandin antifungal agent L-733560, a new water-soluble hybrid of L-705589 and L-731373. Antimicrob Agents Chemother (1995) 2.37
Analysis of pfmdr1 and drug susceptibility in fresh isolates of Plasmodium falciparum from subsaharan Africa. Mol Biochem Parasitol (1995) 2.29
Towards realistic estimates of HCV incidence in Egypt. J Viral Hepat (2012) 2.28
HIV transmission by oral sex. Lancet (1988) 2.27
Life-sustaining treatments during terminal illness: who wants what? J Gen Intern Med (1993) 2.15
Recommendations for end-of-life care in the intensive care unit: The Ethics Committee of the Society of Critical Care Medicine. Crit Care Med (2001) 2.12
Naturally acquired antibodies to sporozoites do not prevent malaria: vaccine development implications. Science (1987) 2.11
Malaria transmitted to humans by mosquitoes infected from cultured Plasmodium falciparum. Am J Trop Med Hyg (1986) 2.09
Single dose kinetics of mefloquine in man. Plasma levels of the unchanged drug and of one of its metabolites. Chemotherapy (1982) 2.06
Treatment of Strongyloides stercoralis infection with ivermectin compared with albendazole: results of an open study of 60 cases. Trans R Soc Trop Med Hyg (1994) 2.03
Plasmodium falciparum: assessment of in vitro growth by [3H]hypoxanthine incorporation. Exp Parasitol (1983) 2.03
What triggers requests for ethics consultations? J Med Ethics (2001) 2.02
Synergistic antimalarial activity of pyrimethamine and sulfadoxine against Plasmodium falciparum in vitro. Am J Trop Med Hyg (1984) 1.99
Chondroitin-4-sulphate (proteoglycan), a receptor for Plasmodium falciparum-infected erythrocyte adherence on brain microvascular endothelial cells. Res Immunol (1996) 1.95
L-arginine-dependent destruction of intrahepatic malaria parasites in response to tumor necrosis factor and/or interleukin 6 stimulation. Eur J Immunol (1991) 1.95
A preliminary pharmacokinetic study of the antimalarial drugs, proguanil and chlorproguanil. J Pharm Pharmacol (1987) 1.95
Virus excretion in the cervicovaginal secretions of pregnant and nonpregnant HIV-infected women. J Acquir Immune Defic Syndr (1993) 1.91
[Environment and malaria in Burundi. Apropos of a malaria epidemic in a non-endemic mountainous region]. Bull Soc Pathol Exot (1993) 1.85
Imported and autochthonous kala-azar in France. BMJ (1991) 1.82
Advance care planning as a process: structuring the discussions in practice. J Am Geriatr Soc (1995) 1.81
Epitope map and processing scheme for the 195,000-dalton surface glycoprotein of Plasmodium falciparum merozoites deduced from cloned overlapping segments of the gene. Proc Natl Acad Sci U S A (1986) 1.77
Point mutations in the dihydrofolate reductase-thymidylate synthase gene and pyrimethamine and cycloguanil resistance in Plasmodium falciparum. Mol Biochem Parasitol (1995) 1.71
Antimoniotungstate (HPA 23) treatment of three patients with AIDS and one with prodrome. Lancet (1985) 1.70
In vitro study of drug sensitivity of Plasmodium falciparum: evaluation of a new semi-micro test. Am J Trop Med Hyg (1983) 1.69
GAPDH, a novel regulator of the pro-apoptotic mitochondrial membrane permeabilization. Oncogene (2006) 1.65
Contrast-enhanced cardiac magnetic resonance in a patient with familial isolated ventricular non-compaction. J Cardiovasc Magn Reson (2004) 1.65
Neuropsychological evaluation of mild head injury. J Neurol Neurosurg Psychiatry (1985) 1.63
Malarone (atovaquone and proguanil hydrochloride): a review of its clinical development for treatment of malaria. Malarone Clinical Trials Study Group. Am J Trop Med Hyg (1999) 1.63
Albendazole as a potential treatment for human hydatidosis. Lancet (1983) 1.62
Dermatoses associated with travel to tropical countries: a prospective study of the diagnosis and management of 269 patients presenting to a tropical disease unit. Clin Infect Dis (1995) 1.59
A new approach to combatting iodine deficiency in developing countries: the controlled release of iodine in water by a silicone elastomer. Am J Public Health (1993) 1.58
Ethical difficulties in clinical practice: experiences of European doctors. J Med Ethics (2007) 1.57
Higher clearance of hepatitis C virus infection in females compared with males. Gut (2006) 1.57
In vitro activity of artemisinin derivatives against African isolates and clones of Plasmodium falciparum. Am J Trop Med Hyg (1993) 1.57
HIV-1-associated cognitive/motor complex: absence of neuronal loss in the cerebral neocortex. Neurology (1993) 1.56
In vitro activities of furoquinoline and acridone alkaloids against Plasmodium falciparum. Antimicrob Agents Chemother (1994) 1.55
Characterization of the 175-kilodalton erythrocyte binding antigen of Plasmodium falciparum. Mol Biochem Parasitol (1990) 1.55
HCV burden of infection in Egypt: results from a nationwide survey. J Viral Hepat (2012) 1.53
Conflict resolution at the end of life. Crit Care Med (2001) 1.53
Desipramine or cyproheptadine for reversing chloroquine resistance? Lancet (1990) 1.52
Plasmodium falciparum and Plasmodium vivax: lactate dehydrogenase activity and its application for in vitro drug susceptibility assay. Exp Parasitol (1995) 1.51
Plasmodium falciparum: molecular characterization of multidrug-resistant Cambodian isolates. Exp Parasitol (1996) 1.48
Parasite virulence factors during falciparum malaria: rosetting, cytoadherence, and modulation of cytoadherence by cytokines. Infect Immun (1993) 1.48
Enhanced Plasmodium falciparum merozoite phagocytosis by monocytes from immune individuals. Infect Immun (1982) 1.46
Abnormalities of the septum pellucidum in schizophrenia. J Neuropsychiatry Clin Neurosci (1989) 1.45
Development of a Plasmodium PCR for monitoring efficacy of antimalarial treatment. J Clin Microbiol (1999) 1.45
Unusual cutaneous cytomegalovirus involvement in patients with acquired immunodeficiency syndrome. Arch Dermatol (1989) 1.44
HIV-associated non-Hodgkin's lymphomas: clinical characteristics and outcome. The experience of the French Registry of HIV-associated tumors. Ann Oncol (1991) 1.44
Chondrex: new marker of joint disease. Clin Chem (1998) 1.43
In vitro antimalarial activity of tetrahydrofolate dehydrogenase inhibitors. Am J Trop Med Hyg (1984) 1.42
Efficacy of amodiaquine against chloroquine-resistant malaria in Cameroon. Lancet (1991) 1.41
Surveillance of heterosexually acquired HIV infection and AIDS. Lancet (1995) 1.40
Subacute clinical forms of Plasmodium falciparum malaria in travelers receiving chloroquine-proguanil prophylaxis. Clin Infect Dis (2001) 1.39
[Plasmodium falciparum malaria: type R1 resistance to quinine in west Africa]. Presse Med (1998) 1.38
[Health cooperation or the unachievable dream]. Med Trop (Mars) (1995) 1.38
Inhibition of in vitro growth of Plasmodium falciparum by immune serum from monkeys. J Infect Dis (1981) 1.37
Surveillance of malaria in European Union countries. Euro Surveill (1998) 1.37
Factors associated with HIV-1 infection among sex workers of Addis Ababa, Ethiopia. AIDS (2001) 1.36
Activation of monocytes and platelets by monoclonal antibodies or malaria-infected erythrocytes binding to the CD36 surface receptor in vitro. J Clin Invest (1989) 1.36
Analysis of pfcrt point mutations and chloroquine susceptibility in isolates of Plasmodium falciparum. Mol Biochem Parasitol (2001) 1.36
A malaria heat-shock-like determinant expressed on the infected hepatocyte surface is the target of antibody-dependent cell-mediated cytotoxic mechanisms by nonparenchymal liver cells. Eur J Immunol (1990) 1.35
In vitro activities of benflumetol against 158 Senegalese isolates of Plasmodium falciparum in comparison with those of standard antimalarial drugs. Antimicrob Agents Chemother (1999) 1.35
Foscarnet nephrotoxicity: mechanism, incidence and prevention. Am J Nephrol (1989) 1.35
Metabolic and cardiovascular risk profiles and hepatitis C virus infection in rural Egypt. Gut (2006) 1.34
Cultivation of the liver forms of Plasmodium vivax in human hepatocytes. Nature (1984) 1.33
Bilateral paramedian thalamic artery infarcts: report of eight cases. J Neurol Neurosurg Psychiatry (1987) 1.32
Visceral leishmaniasis unresponsive to antimonial drugs. III. Successful treatment using a combination of sodium stibogluconate plus allopurinol. Trans R Soc Trop Med Hyg (1985) 1.31
Species- and stage-specific antigens in exoerythrocytic stages of Plasmodium falciparum. Am J Trop Med Hyg (1984) 1.30
Age as a risk factor for severe manifestations and fatal outcome of falciparum malaria in European patients: observations from TropNetEurop and SIMPID Surveillance Data. Clin Infect Dis (2003) 1.29
Leishmania donovani parasitaemia in Kenyan visceral leishmaniasis. Trans R Soc Trop Med Hyg (1985) 1.28
A comparison of three dosage regimens of sodium stibogluconate in the treatment of visceral leishmaniasis in Kenya. J Infect Dis (1983) 1.28
In vitro activity of pyrimethamine, cycloguanil, and other antimalarial drugs against African isolates and clones of Plasmodium falciparum. Am J Trop Med Hyg (1994) 1.28
Effect of raloxifene on breast cancer cell Ki67 and apoptosis: a double-blind, placebo-controlled, randomized clinical trial in postmenopausal patients. Cancer Epidemiol Biomarkers Prev (2001) 1.27
Quality of life following intensive care. J Gen Intern Med (1988) 1.27
The comparative efficacy and tolerability of CGP 56697 (artemether + lumefantrine) versus halofantrine in the treatment of uncomplicated falciparum malaria in travellers returning from the Tropics to The Netherlands and France. Int J Antimicrob Agents (1999) 1.27
HIV-2 infection in two homosexual men in France. Lancet (1987) 1.27
CD127 expression and regulation are altered in the memory CD8 T cells of HIV-infected patients--reversal by highly active anti-retroviral therapy (HAART). Clin Exp Immunol (2006) 1.26
Visceral leishmaniasis unresponsive to antimonial drugs. II. Response to high dosage sodium stibogluconate or prolonged treatment with pentamidine. Trans R Soc Trop Med Hyg (1985) 1.26